Comparison between effect of two drugs- amlodipine and telmisartan on people with high blood pressure on their blood sugar levels,lipid rofile and renal profile.

A comparative study of amlodipine and telmisartan to assess the impact on glycemic status, lipid profile and renal parameters in drug naive hypertensive patients in eastern India. - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/07/071545

Enrollment

220

Registered

2024-07-30

Start date

Unknown

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

Intervention1: Tablet telmisartan: Tablet telmisartan at a dose of 40 mg is given orally once daily to 110 patients selected by computer generated randomisation and physical and biochemical parameters

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patient aged between 18 and 65 years. 2.Patients newly diagnosed with hypertension(systolic blood pressure =140 mm hg and/or diastolic pressure =90 mmhg) 3.Patients with no history of diabetes mellitus,renal disease or hyperlipidemia. 4.Patients who provide informed consent to participate in the study.

Exclusion criteria

Exclusion criteria: 1.Patients who are already taking antihypertensive medications. 2.Patients with a history of allergic reactions to amlodipine or telmisartan. 3.Patients with a history of chronic diseases,such as diabetes mellitus,renal disease,or hyperlipidemia. 5.Pregnant or lactating women. 6.Patients who are unable or unwilling to provide informed consent. 7.Patients who are not taking any other medications that interfere glycemic status,lipid profile and renal parameters.

Design outcomes

Primary

Measure	Time frame
The study will give us knowledge and effectiveness and adverse effects of amlodipine and telmisartan and comparing the effects of these two drugs on glycemic status ,lipid profile and renal parameters. Timepoint: Data will be collected at baseline,3 months and 6 months.	—

Secondary

Measure	Time frame
To study the adverse effect of both the drugs in these patients. Timepoint: Data will be collected at baseline, third & sixth month.	—

Countries

India

Contacts

Public ContactSubhajit Karmakar

MIDNAPORE MEDICAL COLLEGE AND HOSPITAL

ram.narayan.maiti@gmail.com7980356922

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026